Abstract
Approximately 70% of breast cancers, the leading cause of cancer-related mortality worldwide, are positive for the estrogen receptor (ER). Treatment of patients with luminal subtypes is mainly based on endocrine therapy. However, ER positivity is reduced and ESR1 mutations play an important role in resistance to endocrine therapy, leading to advanced breast cancer. Various methodologies for the detection of ESR1 mutations have been developed, and the most commonly used method is next-generation sequencing (NGS)-based assays (50.0%) followed by droplet digital PCR (ddPCR) (45.5%). Regarding the sample type, tissue (50.0%) was more frequently used than plasma (27.3%). However, plasma (46.2%) became the most used method in 2016–2019, in contrast to 2012–2015 (22.2%). In 2016–2019, ddPCR (61.5%), rather than NGS (30.8%), became a more popular method than it was in 2012–2015. The easy accessibility, non-invasiveness, and demonstrated usefulness with high sensitivity of ddPCR using plasma have changed the trends. When using these assays, there should be a comprehensive understanding of the principles, advantages, vulnerability, and precautions for interpretation. In the future, advanced NGS platforms and modified ddPCR will benefit patients by facilitating treatment decisions efficiently based on information regarding ESR1 mutations.
Highlights
This study presented a representative role for ESR1-e2 > coiled-coil domain containing 170 genes (CCDC170) in endocrine therapy resistance
Regarding sample types used for molecular assays, tissues such as formalin-fixed paraffin-embedded (FFPE) and fresh frozen samples were once the major resources for detecting ESR1 mutations
Comparison of the sample types using a wide range of available data showed that plasma obtained from ethylenediaminetetraacetic acid (EDTA), Streck Cell-free DNA blood, and heparinized tubes have become the more appropriate specimens according to the changes in the adopted molecular assays
Summary
A total of 2,179,457 new breast cancer cases and 655,690 cancer-related deaths were estimated worldwide in 2020 according to the Global Cancer Observatory compiled and disseminated by the International Agency for Research on Cancer [1]. The age-standardized incidence rates are highest in Australia/New Zealand; western, northern, and southern Europe; northern America; and southern and eastern Africa [4]. These international distributions are associated with cultural and/or environmental changes due to industrialization. Anthropometry, age at menstruation, hormone intake, lactation, and reproductive patterns, including fewer children and later age at first birth, contribute to the epidemiology of breast cancer [5]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.